{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:56Z","timestamp":1789013336746,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.09.005","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:31:05Z","timestamp":1694892665000},"page":"83-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-1447","authenticated-orcid":false,"given":"Alexandra E.","family":"Rojek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8472-3795","authenticated-orcid":false,"given":"Nicholas","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-6391","authenticated-orcid":false,"given":"Daniel E.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-8185","authenticated-orcid":false,"given":"Yonglin","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-0878","authenticated-orcid":false,"given":"Mariam T.","family":"Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2023.09.005_bib0001","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2023.09.005_bib0002","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2023.09.005_bib0003","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2023.09.005_bib0004","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clml.2023.09.005_bib0005","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.09.005_bib0006","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2023.09.005_bib0007","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2023.09.005_bib0008","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.09.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clml.2023.09.005_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.clml.2023.09.005_bib0011","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.clml.2023.09.005_bib0012","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clml.2023.09.005_bib0013","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.005_sbref0014","year":"2022"},{"issue":"1","key":"10.1016\/j.clml.2023.09.005_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","article-title":"Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer","volume":"39","author":"Liao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.clml.2023.09.005_bib0016","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.09.005_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: improved estimation and validation of optimal cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Softw"},{"key":"10.1016\/j.clml.2023.09.005_bib0018","unstructured":"The R project for statistical computing. Accessed: August 1, 2021. Available at: https:\/\/www.r-project.org\/."},{"issue":"14","key":"10.1016\/j.clml.2023.09.005_bib0019","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2023.09.005_bib0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2023.09.005_bib0021","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.clml.2023.09.005_bib0022","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2023.09.005_bib0023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/ejh.12467","article-title":"Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET\/CT metrics in diffuse large B-cell lymphoma","volume":"94","author":"Adams","year":"2015","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2023.09.005_bib0024","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.clml.2023.09.005_bib0025","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.clml.2023.09.005_bib0026","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2967\/jnumed.115.166769","article-title":"Prospective study of 3\u2019-deoxy-3\u2019-18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma","volume":"57","author":"Sch\u00f6der","year":"2016","journal-title":"J Nucl Med"},{"issue":"30","key":"10.1016\/j.clml.2023.09.005_bib0027","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2023.09.005_bib0028","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-16-0783","article-title":"Molecular profile and FDG-PET metabolic volume at staging in DLBCL-response","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.09.005_bib0029","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1182\/blood-2021-153739","article-title":"Metabolic PET\/CT analysis of aggressive non-hodgkin lymphoma prior to axicabtagene ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity","volume":"138","author":"Breen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.09.005_bib0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","article-title":"Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","volume":"107","author":"Kostakoglu","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.09.005_bib0031","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2023.09.005_bib0032","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/bloodadvances.2022008294","article-title":"Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy","volume":"7","author":"Wudhikarn","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2023.09.005_bib0033","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.09.005_bib0034","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.09.005_bib0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.005_bib0036","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1182\/blood-2022-159217","article-title":"Improvement in lymphoma CAR-T outcomes over time in the UK - CAR-T learning curve or better bridging?","volume":"140","author":"Boyle","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.09.005_bib0037","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.09.005_bib0038","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The International prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2023.09.005_bib0039","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:55Z","timestamp":1761871435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023015537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023015537"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}